A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene mutation behaves differently from other variants.
Approximately 25-30% of lung cancer patients lack mutations targeted by current therapies, necessitating novel approaches. New targets, including MTAP deletions, SMARC4, and p53 mutations, show ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results